Cost and benefits of specific immune therapy (SIT) of polling allergy patients with asthma and/or rhinitis;Kosten und nutzen der hyposensibilisierung bei allergischem asthma und rhinitis

Gesundheitsokonomie und Qualitatsmanagement

Volumn 8, Issue 3, 2003, Pages 179-186

  Greiner, W ^a   Graf v d Schulenburg, J M ^a   Gillissen, A ^b  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b Robert Koch Klinik   (Germany)

Author keywords

Asthma; Cost analysis; Polling allergy; Rhinitis; Specific immune therapy

Indexed keywords

ALLERGEN; POLLEN EXTRACT;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; AMBULATORY CARE; ARTICLE; ASTHMA; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE DURATION; DRUG COST; DRUG EFFECT; DRUG SPECIFICITY; ECONOMIC EVALUATION; GENERAL PRACTICE; HEALTH CARE COST; HOSPITAL COST; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; POLLEN ALLERGY; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY; RHINITIS; SENSITIVITY ANALYSIS; STANDARDIZATION; SYMPTOMATOLOGY;

EID: 0041825151     PISSN: 14322625     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40480     Document Type: Article

References (12)

1. Bento AM, Hershenson MB. Airway remodeling - potential contributions of subepithelial fibrosis and airway smooth muscle hypertrophy/hyperplasia to airway narrowing in asthma. Allergy Asthma Proc 1998; 19: 353-358
2. Bousquet J, Demoly P, Michel FB. Specific immunotherapy in rhinitis and asthma. Ann Allergy Asthma Immunol 2001; 87: 38-42
3. Durham SR et al. Long-term clinical efficacy of grass-pollen immunotherapy. New Engl J Med 1999; 341: 468-475
4. Hannoveraner Konsensus Gruppe. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - Revidierte Fassung des Hannoveraner Konsens. Gesundh ökon Qual manag 1999; 4: A62-A65
5. Jacobsen L, Nüchel-Petersen BN, Wihl JA, Løwenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts - IV. Results from long-term (6 year) follow-up. Allergy 1997; 52: 914-920
6. Mosbech H, Østerballe O. Does the effect of immunotherapy last after termination of treatment. Allergy 1988; 43: 523-529
7. Petersen BN et al. Immunotherapy with partially purified and standardized tree pollen extracts. Allergy 1988; 43: 353-362
8. Probst D, Müller D. Asthma bronchiale und Foradil. Stuttgart. u.a: Thieme, 1997
9. Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. PharmacoEconomics 2000; 17: 37-52
10. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Brit Med J 1991; 302: 265-269
11. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy - efficacy and safety during a 4-year follow-up study. Allergy 1995; 50: 405-413
12. Wettengel R et al. Empfehlungen zur Asthmatherapie bei Kindern und Erwachsenen. Pneumologie 1998; 52: 591-601